Cue Biopharma, Inc. — Director's Dealing 2021

Nov 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cue Biopharma, Inc. (CUE)
CIK: 0001645460
Period of Report: 2021-11-15

Reporting Person: Suri Anish (President and CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-15	Common Stock	M	8000	$8.26	Acquired	102038	Direct
2021-11-15	Common Stock	S	8000	$18.05	Disposed	94038	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-15	Stock Option (right to buy)	$8.26	M	8000	Disposed	2025-08-14	Common Stock (8000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.21, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3: The option vests in eight equal semi-annual installments beginning November 14, 2018.